| Epidemiology from Literature | | Cohort | Year | Country | Test | Subjects | Positive (%) | Bibliography | | 1.10 - Any allergy symptom, Diagnosed | 2010 | Italy | IgE | 16408 | 1.880 | 20100301, Scala E
| | 6.2 - General Population (Adults) | 2012 | Sweden | IgE | 371 | 1.080 | 20120528, Patelis A
| | 1.5 - Atopic Dermatitis, Diagnosed | 2013 | Germany | IgE | 140 | 5.000 | 20130111, Ott H
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 1994 | Austria | IgE (IB) | 110 | 35.000 | | | 4.1.2 - Heterologous Source Sensitized (Symptoms, SPT) | 2011 | China | IgE | 100 | 2.000 | 20111214, Zheng YW
| | 5.2.4 - Source Exposed, Adults (Symptoms, IgE) | 2012 | Sweden | IgE | 100 | 19.000 | 20120420, Nilsson OB
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2012 | Belgium | IgE | 99 | 1.010 | 20110223, De Knop KJ
| | 1.2.1 - Asthma, Diagnosed (Adults) | 2012 | Sweden | IgE | 96 | 5.210 | 20120528, Patelis A
| | 3.2.1 - Source Sensitized (IgE) | 2010 | Sweden | IgE | 89 | 25.000 | 20100719, Madhurantakam C
| | 1.10 - Any allergy symptom, Diagnosed | 2010 | Belgium | IgE | 86 | 11.630 | 20101214, Gadisseur R
| | 1.11 - Esophagitis, Diagnosed | 2013 | Netherlands | IgE | 76 | 5.300 | 20131020, van Rhijn BD
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 1996 | France | IgE | 43 | 39.000 | | | 5.3.1 - Source Exposed (Symptoms, IgE) | 2011 | Luxembourg | IgE | 43 | 39.530 | 20111122, Hilger C
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Belgium | IgE | 37 | 5.405 | 20090826, Ebo DG
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2010 | Spain / Sweden / USA | IgE | 37 | 16.220 | 20100609, Mattsson L
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | Sweden | IgE | 37 | 8.000 | 20140127, Konradsen JR
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2009 | Sweden | IgE | 37 | 16.210 | 20090109, Mattsson L
| | 1.11 - Esophagitis, Diagnosed | 2013 | Switzerland | IgE | 35 | 2.860 | 20130605, Simon D
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2013 | Luxembourg | IgE | 35 | 2.860 | 20131227, Hilger C
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | Sweden | IgE | 28 | 7.000 | 20140127, Konradsen JR
| | 10.1 - Normal Control | 2012 | Belgium | IgE | 27 | 0.000 | 20110223, De Knop KJ
| | 10.1 - Normal Control | 2009 | Belgium | IgE | 26 | 0.000 | 20091121, Ebo DG
| | 1.5 - Atopic Dermatitis, Diagnosed | 2014 | Korea, Republic of | IgE | 25 | 4.000 | 20140821, Choi JS
| | 5.4.2 - Source Exposed (Symptoms, SPT, high IgE) | 2004 | Finland | IgE (IB) | 25 | 48.000 | | | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2009 | Belgium | IgE | 22 | 9.090 | 20091121, Ebo DG
| | 1.5 - Atopic Dermatitis, Diagnosed | 2009 | Germany | IgE | 20 | 15.000 | 20091005, Ott H
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2009 | Belgium | IgE | 20 | 0.000 | 20091121, Ebo DG
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2003 | Austria | IgE | 20 | 35.000 | | | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2013 | United States | IgE | 8 | 100.000 | 20130128, Posthumus J
|
|
Loading...
Can f 3
